

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/apm-21-443">http://dx.doi.org/10.21037/apm-21-443</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response</b> (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes, particular raw data.
2	If not, would you like to share the reason for your decision?	
3	What data in particular will be shared?	The survival data in particular will be shared, which has seldom been provided in previous studies.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	No
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in studies of antiangiogenic therapy in the treatment of small cell lung cancer.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of endostatin in small cell lung cancer patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zhaoyi0411@126.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared. And the data was based on small sample sizes, it need to be confirmed by phase 3 clinical studies with larger sample sizes.